Free Trial

Vanda Pharmaceuticals (VNDA) Competitors

Vanda Pharmaceuticals logo
$5.38 +0.15 (+2.87%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$5.38 0.00 (0.00%)
As of 10/15/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VNDA vs. OPK, DVAX, INVA, ZBIO, GERN, MYGN, VSTM, LXRX, RIGL, and EBS

Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry.

Vanda Pharmaceuticals vs. Its Competitors

OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

OPKO Health has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 49.7% of OPKO Health shares are held by company insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

OPKO Health currently has a consensus price target of $2.63, indicating a potential upside of 72.70%. Vanda Pharmaceuticals has a consensus price target of $16.50, indicating a potential upside of 206.69%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OPKO Health
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
Vanda Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

In the previous week, OPKO Health had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 5 mentions for OPKO Health and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.62 beat OPKO Health's score of 0.50 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OPKO Health
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

OPKO Health has a net margin of -26.68% compared to Vanda Pharmaceuticals' net margin of -32.90%. Vanda Pharmaceuticals' return on equity of -12.89% beat OPKO Health's return on equity.

Company Net Margins Return on Equity Return on Assets
OPKO Health-26.68% -13.17% -8.28%
Vanda Pharmaceuticals -32.90%-12.89%-10.47%

Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OPKO Health$713.10M1.69-$53.22M-$0.25-6.08
Vanda Pharmaceuticals$198.77M1.60-$18.90M-$1.13-4.76

Summary

OPKO Health beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VNDA vs. The Competition

MetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$309.04M$3.37B$6.11B$10.46B
Dividend YieldN/A2.29%5.73%4.77%
P/E Ratio-4.7622.7785.3627.36
Price / Sales1.60465.72601.96132.92
Price / CashN/A46.7037.4661.86
Price / Book0.5810.5512.426.81
Net Income-$18.90M-$52.58M$3.32B$276.80M
7 Day Performance-1.28%0.09%0.57%0.42%
1 Month Performance20.63%15.61%10.52%7.86%
1 Year Performance9.80%15.13%72.99%41.24%

Vanda Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VNDA
Vanda Pharmaceuticals
4.1277 of 5 stars
$5.38
+2.9%
$16.50
+206.7%
+12.1%$309.04M$198.77M-4.76290
OPK
OPKO Health
4.2039 of 5 stars
$1.58
+1.3%
$2.63
+66.1%
+3.4%$1.24B$713.10M-6.322,997News Coverage
DVAX
Dynavax Technologies
4.5682 of 5 stars
$10.14
+0.4%
$24.33
+140.0%
-7.7%$1.18B$277.25M-22.04350
INVA
Innoviva
4.825 of 5 stars
$17.42
-0.3%
$37.60
+115.8%
-12.5%$1.10B$358.71M56.20100
ZBIO
Zenas BioPharma
2.2723 of 5 stars
$23.03
+5.8%
$36.67
+59.2%
N/A$916.31M$15M-6.49N/ATrending News
Insider Trade
Analyst Revision
Gap Up
GERN
Geron
2.4971 of 5 stars
$1.28
-5.2%
$3.79
+195.8%
-69.5%$861.32M$76.99M-9.8570News Coverage
MYGN
Myriad Genetics
3.5668 of 5 stars
$7.99
-0.9%
$12.45
+55.9%
-66.2%$749.94M$837.60M-1.872,700Analyst Forecast
VSTM
Verastem
2.9561 of 5 stars
$8.61
-1.0%
$13.29
+54.3%
+200.3%$535.44M$10K-2.6350News Coverage
LXRX
Lexicon Pharmaceuticals
2.7713 of 5 stars
$1.55
+9.9%
$3.23
+108.1%
-14.5%$512.39M$31.08M-4.70140Positive News
Gap Up
RIGL
Rigel Pharmaceuticals
3.6965 of 5 stars
$28.90
+1.3%
$38.20
+32.2%
+83.7%$511.93M$179.28M5.34160
EBS
Emergent Biosolutions
4.2444 of 5 stars
$9.16
+0.1%
$13.50
+47.4%
+4.7%$488.16M$1.04B3.742,420

Related Companies and Tools


This page (NASDAQ:VNDA) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners